Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma | Zendy

Hadi Atabati | Zendy; Amir Raoofi | Zendy; Abdollah Amini | Zendy; Reza Mastery Farahani | Zendy

Open Access

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma

Author(s) -

Hadi Atabati,

Amir Raoofi,

Abdollah Amini,

Reza Mastery Farahani

Publication year - 2018

Publication title -

open access macedonian journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.288

H-Index - 17

ISSN - 1857-9655

DOI - 10.3889/oamjms.2018.455

Subject(s) - cish , chromogenic in situ hybridization , medicine , immunohistochemistry , breast cancer , breast carcinoma , oncology , ductal carcinoma , cancer , pathology , in situ hybridization , gene , gene expression , biology , genetics

In patients with breast cancer, HER2 gene expression is of a great importance in reacting to Herceptin treatment. To evaluate this event, immunohistochemistry (IHC) has been done routinely on the basis of scoring it and so the patients were divided into 4 groups. Lately, as there have been disagreements about how to treat score 2 patients, chromogenic in situ hybridization (CISH) and florescence in situ hybridization (FISH) are introduced. Since CISH method is more convenient than FISH for gene amplification study, FISH has been substituted by CISH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research